ReviewNature immunology2023
The immunometabolic ecosystem in cancer.
Review in Nature immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A bibliometric analysis of inflammation and thyroid carcinoma: research trends and future perspectives.Frontiers in oncology · 2025Pooled it
- Senescent-Like Neutrophils Shape Angiogenic Immunosuppressive Niches in Colorectal Cancer Liver Metastasis.Cancer discovery · 2026Article
- Metabolomics-Driven Discovery of Targets for Hepatocytotoxicity Induced by Triphenyltin Chloride through Mitochondrial Function Involving HSD17B10 and HADH.Environment & health (Washington, D.C.) · 2026Article
- Bufalin-Loaded Multifunctional Nanodrugs for Cancer Therapy: Mechanisms, Delivery Strategies, and Translational Perspectives.Biomolecules · 2026Review
- Development and internal validation of a six-gene prognostic model based on galactose metabolism for overall survival in lung adenocarcinoma.Translational cancer research · 2026Article
- HAdvanced materials (Deerfield Beach, Fla.) · 2026Article
- Spleen-associated macrophage alterations and embryo viability in a murine model of recurrent spontaneous abortion.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Article
- Engineering an immuno-nanoprodrug: Photo-controlled pyroptosis synergizing with acid-activatable immunometabolic blockade for potent cancer immunotherapy.Acta pharmaceutica Sinica. B · 2026Article
- Metabolic and transcriptional plasticity supports CD8Immunity · 2026Article
- Integrated single-cell and transcriptomic analysis of CD8Translational cancer research · 2026Article
- CALB2 mediates tumor progression and immune escape in colorectal cancer by shaping an inhibitory immune microenvironment.Frontiers in immunology · 2026Article
- Early physiological phenotypes and survival outcomes in advanced non-small cell lung cancer: a longitudinal study of dynamic muscle loss and functional decline.Frontiers in oncology · 2026Article
- Metabolic Checkpoints in CD8International journal of biological sciences · 2026Review
- Photoactivatable immunostimulatory nanoengineered microalgae for boosting cascade-activated antitumor immunity.Science advances · 2025Article
- Artemisinin and Its Derivatives from Molecular Mechanisms to Clinical Applications: New Horizons Beyond Antimalarials.International journal of molecular sciences · 2025Review
- mCancer cell international · 2025Article
- Targeting TP53TG1: a promising prognostic biomarker and therapeutic target for personalized cancer therapy.Discover oncology · 2025Review
- Immunometabolism of regulatory T cells in cancer.Oncogene · 2025Review
- Immune cell metabolism in cancer drug resistance: Advances in target discovery and clinical translation.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- FAHD1 and mitochondrial metabolism: a decade of pioneering discoveries.The FEBS journal · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Our increased understanding of how key metabolic pathways are activated and regulated in malignant cells has identified metabolic vulnerabilities of cancers. Translating this insight to the clinics, however, has proved challenging. Roadblocks limiting efficacy of drugs targeting cancer metabolism may lie in the nature of the metabolic ecosystem of tumors. The exchange of metabolites and growth factors between cancer cells and nonmalignant tumor-resident cells is essential for tumor growth and evolution, as well as the development of an immunosuppressive microenvironment. In this Review, we will examine the metabolic interplay between tumor-resident cells and how targeted inhibition of specific metabolic enzymes in malignant cells could elicit pro-tumorigenic effects in non-transformed tumor-resident cells and inhibit the function of tumor-specific T cells. To improve the efficacy of metabolism-targeted anticancer strategies, a holistic approach that considers the effect of metabolic inhibitors on major tumor-resident cell populations is needed.
Indexed as
Identifiers
38012409What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.